Comparison 4. Triptans vs placebo in adolescents, subgroup analysis.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 Pain‐free by route (oral or intranasal)	21	6764	Risk Ratio (M‐H, Random, 95% CI)	1.32 [1.19, 1.47]
4.1.1 Oral	15	4415	Risk Ratio (M‐H, Random, 95% CI)	1.22 [1.08, 1.38]
4.1.2 Intranasal	6	2349	Risk Ratio (M‐H, Random, 95% CI)	1.52 [1.32, 1.75]
4.2 Sumatriptan vs placebo by route (oral or intranasal)	10	2415	Risk Ratio (M‐H, Random, 95% CI)	1.27 [1.10, 1.48]
4.2.1 Intranasal	4	1490	Risk Ratio (M‐H, Random, 95% CI)	1.37 [1.15, 1.63]
4.2.2 Oral	6	925	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.75, 1.43]
4.3 Zolmitriptan vs placebo by route (oral or intranasal)	4	1532	Risk Ratio (M‐H, Random, 95% CI)	1.66 [1.16, 2.38]
4.3.1 Intranasal	2	859	Risk Ratio (M‐H, Random, 95% CI)	1.87 [1.46, 2.40]
4.3.2 Oral	2	673	Risk Ratio (M‐H, Random, 95% CI)	1.94 [0.42, 9.07]
4.4 Pain‐free by preventive medication	21	6764	Risk Ratio (M‐H, Random, 95% CI)	1.32 [1.19, 1.47]
4.4.1 Preventive medication not permitted	8	1658	Risk Ratio (M‐H, Random, 95% CI)	1.39 [1.14, 1.69]
4.4.2 Preventive medication permitted	8	2316	Risk Ratio (M‐H, Random, 95% CI)	1.28 [1.04, 1.56]
4.4.3 Unsure	5	2790	Risk Ratio (M‐H, Random, 95% CI)	1.33 [1.11, 1.61]